

## Blincyto® (blinatumomab) – Expanded Dosing and New Warnings

- On September 1, 2016, <u>Amgen announced</u> the FDA approval of <u>Blincyto (blinatumomab)</u> to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
  - This indication was approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials.
  - Prior to this approval, information on the use of Blincyto in pediatric patients was limited. Thus, dosing in patients < 45 kg was not provided.</li>
- The expanded approval for Blincyto is based on results from a phase 1/2, open-label, single-arm study, which evaluated the efficacy and safety of Blincyto in pediatric patients with relapsed or refractory B-cell precursor ALL.
  - In addition, the steady-state concentrations of Blincyto were shown to be comparable in adult and pediatric patients at the equivalent dose levels based on body surface area-based regimens.
- Blincyto carries a boxed warning regarding cytokine release syndrome and neurological toxicities.
- The updated label for Blincyto also includes new warnings regarding pancreatitis and immunization.
  - Fatal pancreatitis has been reported in patients receiving Blincyto in combination with dexamethasone in clinical trials and the post-marketing setting. Patients who develop signs and symptoms of pancreatitis should be evaluated. Management of pancreatitis may require either temporary interruption or discontinuation of Blincyto and dexamethasone.
  - In addition, the safety of immunization with live viral vaccines during or following Blincyto therapy has not been studied. Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of Blincyto treatment, during treatment, and until immune recovery following last cycle of Blincyto.
- A single treatment cycle of Blincyto consists of 28 days of continuous intravenous infusion followed by a 14-day treatment-free interval (total 42 days). A treatment course consists of up to 2 cycles of Blincyto for induction followed by 3 additional cycles for consolidation treatment (up to a total of 5 cycles).
  - For patients weighing < 45 kg, in cycle 1, administer Blincyto at 5 mcg/m² per day on days 1 7 and at 15 mcg/m² per day on days 8 28. For subsequent cycles, administer Blincyto at 15 mcg/m² per day on days 1 28.</li>
  - For patients weighing ≥ 45 kg, in cycle 1, administer Blincyto at 9 mcg/day on days 1 7 and at 28 mcg/day on days 8 – 28. For subsequent cycles, administer Blincyto at 28 mcg/day on days 1-28.
  - Hospitalization is recommended for the first 9 days of the first cycle and the first 2 days of the second cycle. For all subsequent cycle starts and re-initiation (eg, if treatment is interrupted for 4 or more hours), supervision by a healthcare professional or hospitalization is recommended.
  - Premedication with dexamethasone is recommended.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.